Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality

Kevin Outterson; Unni Gopinathan; Charles Clift; Anthony D So; Chantal M Morel; John-Arne Røttingen

doi:10.1371/journal.pmed.1002043

Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality

PLoS Med. 2016 Jun 14;13(6):e1002043. doi: 10.1371/journal.pmed.1002043. eCollection 2016 Jun.

Authors

Kevin Outterson^{1

2

3}, Unni Gopinathan^{4

5}, Charles Clift^{2

3}, Anthony D So^{6

7}, Chantal M Morel^{3

8}, John-Arne Røttingen^{2

3

5

9

10}

Affiliations

¹ Boston University School of Law, Boston, Massachusetts, United States of America.
² Chatham House Centre for Global Health Security, London, United Kingdom.
³ DRIVE-AB, Innovative Medicines Initiative, Geneva, Switzerland.
⁴ Oslo University Hospital, Oslo, Norway.
⁵ Norwegian Institute of Public Health, Oslo, Norway.
⁶ Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
⁷ ReAct - Action on Antibiotic Resistance, Uppsala, Sweden.
⁸ London School of Economics, London, United Kingdom.
⁹ University of Oslo, Oslo, Norway.
¹⁰ Harvard School of Public Health, Boston, Massachusetts, United States of America.

Abstract

Kevin Outterson and colleagues outline a model to address access, conservation, and innovation of antibiotics.

MeSH terms

Anti-Bacterial Agents*
Commerce / economics*
Drug Industry / economics*
Investments*
Models, Theoretical
Pharmaceutical Research / economics*

Substances

Anti-Bacterial Agents

Grants and funding

No specific funding supported the work.